PCVX News and Press, Vaxcyte Inc. From 01/02/24

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...

2023-12-28 12:12:14 ET Summary Today, we take a deeper look at Vaxcyte, whose stock has seen a sharp rally in the past four weeks and is approaching analyst price targets. The company's lead candidate, VAX-24, has potential to be the best-in-class pneumococcal conjugate vaccine. ...

2023-12-21 21:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-05 06:33:06 ET Vaxcyte's ( NASDAQ: PCVX ) investigational 24-valent pneumococcal conjugate vaccine (PCV), VAX-24, has shown a safety and tolerability profile comparable to Pfizer's ( PFE ) Prevnar 20 shot for the prevention of invasive pneumococcal disease in healthy adu...

-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards ...

SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Jacks Lee to its Board of Directors. ...

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial M...

-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximate...

2023-11-06 17:51:44 ET More on Vaxcyte Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling Strong Financials And Pipeline Position Vaxcyte For Success For further details see: Vaxcyte GAAP EPS of -$0.91

-- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24; Topline Phase 3 Data in Adults Expected in 2025 -- -- Received FDA Clearance of VAX-31 Adult IND Application; Phase 1/2 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024 -- ...